[{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation Medicine \/ Repare Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Lunresertib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : Lunresertib,Camonsertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 06, 2024

                          Lead Product(s) : Lunresertib,Camonsertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Repare Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 23, 2024

                          Lead Product(s) : Lunresertib,Camonsertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 30, 2024

                          Lead Product(s) : Lunresertib,Debio 0123

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Debiopharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2024

                          Lead Product(s) : Lunresertib,Camonsertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : Debio 0123

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 01, 2024

                          Lead Product(s) : Debio 0123,Lunresertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Debiopharm

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 06, 2023

                          Lead Product(s) : Lunresertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Canadian Cancer Trials Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 20, 2022

                          Lead Product(s) : Lunresertib,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 21, 2021

                          Lead Product(s) : Lunresertib,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : RP-6306

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 30, 2021

                          Lead Product(s) : Lunresertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank